Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
GC Biopharma Corp. (006280.KS)
KRW120,600.00
-600.00 (-0.50%)
KR KSC Healthcare Medical - Pharmaceuticals
Address
107, Ihyeon-ro 30beon-gil
Yongin-Si, KR
Yongin-Si, KR
CEO
Eun-chul Huh
Website
gcbiopharma.com
IPO
2000-01-04
ISIN KR7006280002
Also trades on
Korea Exchange · 005257.KS (KRW)
Korea Exchange · 006280.KS (KRW)
Description
GC Biopharma Corp. is a pharmaceutical enterprise primarily involved in the production and distribution of various medical products. Its extensive portfolio encompasses specialized treatments for blood-related conditions, non-prescription remedies, general medications, and immunizations, among other therapeutic solutions. The company was established on November 1, 1969, and its principal corporate offices are situated in Yongin, South Korea.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW120,600.00
-600.00 (-0.50%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
57.9K
Beta
0.73
Float Shares
5.45M
Free Float %
47.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.32% | -6.89% | -11.01% | -14.77% | -8.08% | -22.90% | -8.96% | -0.24% | -62.13% | -39.46% | +1,615.34% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
120,600.00
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 6 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.52
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth+18.5% Q1'26: +13.5% (vs Q1'25)
-
EPS growth+82.2% Q1'26: -31.0% (vs Q1'25)
-
FCF margin+0.7% Q1'26: -13.2% (vs Q1'25)
-
EBIT margin+3.4% Q1'26: +2.7% (vs Q1'25)
-
ROIC+2.3% Q1'26: +1.5% (vs Q1'25)
-
Share dilution+0.0% Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA6.32× Q1'26: 6.63× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 6 EPS Ana. |
Dec 2028 1 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.05T
est: 1.05T (+0.2%)
|
1.20T
est: 1.19T (+0.8%)
|
1.29T
est: 1.30T (-0.6%)
|
1.33T
est: 1.33T (+0.5%)
|
1.37T
est: 1.37T (-0.1%)
|
1.50T
est: 1.49T (+0.8%)
|
1.54T
est: 1.60T (-3.9%)
|
1.71T
est: 1.64T (+4.3%)
|
1.63T
est: 1.63T (-0.3%)
|
1.68T
est: 1.69T (-0.5%)
|
1.99T
est: 1.99T (+0.2%)
|
2.04T
1.99T – 2.10T
+2.8% YoY
|
2.17T
2.10T – 2.24T
+6.0% YoY
|
2.34T
2.27T – 2.41T
+7.8% YoY
|
| EBITDA |
120.08B
est: 92.10B (+30.4%)
|
115.85B
est: 104.66B (+10.7%)
|
115.06B
est: 114.11B (+0.8%)
|
97.77B
est: 116.90B (-16.4%)
|
57.80B
est: 120.78B (-52.1%)
|
168.79B
est: 131.43B (+28.4%)
|
159.01B
est: 140.90B (+12.9%)
|
187.04B
est: 144.53B (+29.4%)
|
109.81B
est: 143.61B (-23.5%)
|
80.36B
est: 137.10B (-41.4%)
|
155.46B
est: 161.49B (-3.7%)
|
165.96B
161.43B – 170.56B
+2.8% YoY
|
175.98B
170.78B – 181.80B
+6.0% YoY
|
189.75B
184.35B – 195.53B
+7.8% YoY
|
| EBIT |
133.90B
est: 50.05B (+167.5%)
|
84.90B
est: 56.88B (+49.3%)
|
78.46B
est: 62.02B (+26.5%)
|
57.76B
est: 63.53B (-9.1%)
|
11.29B
est: 65.64B (-82.8%)
|
120.46B
est: 71.43B (+68.6%)
|
103.53B
est: 76.58B (+35.2%)
|
122.22B
est: 78.55B (+55.6%)
|
33.91B
est: 78.05B (-56.6%)
|
-670.49M
est: 65.24B (-101.0%)
|
67.81B
est: 76.84B (-11.8%)
|
78.97B
76.81B – 81.16B
+2.8% YoY
|
83.74B
81.26B – 86.50B
+6.0% YoY
|
90.29B
87.72B – 93.04B
+7.8% YoY
|
| Net Income |
94.97B
est: 97.82B (-2.9%)
|
62.97B
est: 58.66B (+7.3%)
|
53.25B
est: 63.71B (-16.4%)
|
34.43B
est: 35.85B (-4.0%)
|
-11.29B
est: 30.19B (-137.4%)
|
81.05B
est: 96.86B (-16.3%)
|
123.21B
est: 106.16B (+16.1%)
|
65.45B
est: 66.54B (-1.6%)
|
-26.63B
est: -15.35B (-73.5%)
|
-26.28B
est: -17.26B (-52.2%)
|
-4.67B
est: 26.16B (-117.9%)
|
32.74B
13.10B – 68.27B
+25.2% YoY
|
57.05B
20.99B – 96.75B
+74.3% YoY
|
83.59B
80.50B – 86.90B
+46.5% YoY
|
| SGA |
77.59B
est: 96.87B (-19.9%)
|
82.26B
est: 110.08B (-25.3%)
|
84.41B
est: 120.03B (-29.7%)
|
92.18B
est: 122.96B (-25.0%)
|
112.27B
est: 127.04B (-11.6%)
|
145.24B
est: 138.24B (+5.1%)
|
169.13B
est: 148.20B (+14.1%)
|
165.07B
est: 152.02B (+8.6%)
|
134.40B
est: 151.05B (-11.0%)
|
130.12B
est: 151.93B (-14.4%)
|
166.30B
est: 178.95B (-7.1%)
|
183.90B
178.89B – 189.01B
+2.8% YoY
|
195.01B
189.25B – 201.46B
+6.0% YoY
|
210.27B
204.29B – 216.67B
+7.8% YoY
|
| EPS |
8,213.00
est: 8,570.78 (-4.2%)
|
5,451.00
est: 5,140.03 (+6.1%)
|
4,665.00
est: 5,582.09 (-16.4%)
|
3,017.00
est: 3,141.20 (-4.0%)
|
-988.98
est: 2,645.33 (-137.4%)
|
7,101.00
est: 8,486.88 (-16.3%)
|
10,795.00
est: 9,301.86 (+16.1%)
|
5,734.87
est: 5,829.89 (-1.6%)
|
-2,333.42
est: -1,345.14 (-73.5%)
|
-2,302.62
est: -1,512.31 (-52.3%)
|
-409.51
est: 2,291.71 (-117.9%)
|
2,868.46
1,147.41 – 5,981.37
+25.2% YoY
|
4,998.57
1,839.20 – 8,476.56
+74.3% YoY
|
7,323.76
7,052.90 – 7,613.78
+46.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-09 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-06-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-06-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-06-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-06-02 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-06-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-10 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
231.00B
OE per share TTM
20,248.73
Owner's Yield
16.35%
Maintenance CapEx ratio
25.58%
Maint CapEx / Avg PPE
53.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
33.75M
Shares Outstanding
11.41M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Eun-chul Huh | CEO, President & Chairman | 1B | male |
| In-Jae Lee | Senior MD | — | male |
| Jae-Wook Jeong | Head of Research and Development & Director | — | male |
| Sean Zam | Head of Sales & Marketing | — | male |
| Woong Shin | Head of Operations Division & Director | — | male |
| Young Sup Huh | Executive Vice President | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 006280.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
